Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W Goldman; Mikhail Dvorkin; Yuanbin Chen; Niels Reinmuth; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian J Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Oleksandr Voitko; Artem Poltoratskiy; Santiago Ponce; Francesco Verderame; Libor Havel; Igor Bondarenko; Andrzej Każarnowicz; György Losonczy; Nikolay V Conev; Jon Armstrong; Natalie Byrne; Piruntha Thiyagarajah; Haiyi Jiang; Luis Paz-Ares; Mikhail Dvorkin; Dmytro Trukhin; Galina Statsenko; Nataliia Voitko; Artem Poltoratskiy; Igor Bondarenko; Yuanbin Chen; Andrzej Kazarnowicz; Luis Paz-Ares; Mustafa Özgüroglu; Nikolay Conev; Maximilian Hochmair; Otto Burghuber; Libor Havel; Irfan Çiçin; György Losonczy; Vladimir Moiseenko; Mustafa Erman; Dariusz Kowalski; Marek Wojtukiewicz; Hryhoriy Adamchuk; Alexander Vasilyev; Serhii Shevnia; Spartak Valev; Niels Reinmuth; Jun Ho Ji; Maria Amelia Insa Molla; Grygorii Ursol; Anne Chiang; Sylvia Hartl; Zsolt Horváth; Gábor Pajkos; Francesco Verderame; Katsuyuki Hotta; Sang-We Kim; Alexey Smolin; Tuncay Göksel; Shaker Dakhil; Jaromir Roubec; Krisztina Bogos; Marina Chiara Garassino; Robin Cornelissen; Jong-Seok Lee; Maria Rosario Garcia Campelo; Marta Lopez Brea; Ahmet Alacacioglu; Ignacio Casarini; Rumyana Ilieva; Ivan Tonev; Attila Somfay; Jair Bar; Alona Zer Kuch; Mauro Minelli; Roberta Bartolucci; Fausto Roila; Haruhiro Saito; Koichi Azuma; Gyeong-Won Lee; Alexander Luft; Michal Urda; Juan Ignacio Delgado Mingorance; Margarita Majem Tarruella; David Spigel; Krassimir Koynov; Milada Zemanova; Jens Panse; Christian Schulz; Zsolt Pápai Székely; Veronika Sárosi; Angelo Delmonte; Anna Cecilia Bettini; Makoto Nishio; Isamu Okamoto; Lizza Hendriks; Slawomir Mandziuk; Yun Gyoo Lee; Lyubov Vladimirova; Dolores Isla Casado; Manuel Domine Gomez; Alejandro Navarro Mendivil; Teresa Morán Bueno; Shang-Yin Wu; Jeanna Knoble; Jana Skrickova; Violetka Venkova; Werner Hilgers; Eckart Laack; Helge Bischoff; Andrea Fülöp; Ibolya Laczó; Judit Kósa; András Telekes; Tatsuya Yoshida; Shintaro Kanda; Toyoaki Hida; Hidetoshi Hayashi; Tadashi Maeda; Tetsuji Kawamura; Yasuharu Nakahara; Niels Claessens; Ki Hyeong Lee; Chao-Hua Chiu; Sheng-Hao Lin; Chien-Te Li; Ahmet Demirkazik; Eric Schaefer; Petros Nikolinakos; Jeffrey Schneider; Sunil Babu; Bernd Lamprecht; Michael Studnicka; Carlos Fausto Nino Gorini; Juraj Kultan; Vitezslav Kolek; Pierre-Jean Souquet; Denis Moro-Sibilot; Maya Gottfried; Egbert Smit; Kyung Hee Lee; Peter Kasan; Jozef Chovanec; Olexandr Goloborodko; Oleksii Kolesnik; Yuriy Ostapenko; Shailendra Lakhanpal; Basir Haque; Winston Chua; Joseph Stilwill; Susana Noemi Sena; Gustavo Colagiovanni Girotto; Pedro Rafael Martins De Marchi; Fabricio Augusto Martinelli de Oliveira; Pedro Dos Reis; Rositsa Krasteva; Yanqiu Zhao; Chengshui Chen; Leona Koubkova; Gilles Robinet; Christos Chouaid; Christian Grohe; Jürgen Alt; Eszter Csánky; Éva Somogyiné Ezer; Norman Isaac Heching; Young Hak Kim; Shinji Aatagi; Shoichi Kuyama; Daijiro Harada; Naoyuki Nogami; Hiroshi Nokihara; Hisatsugu Goto; Agnes Staal van den Brekel; Eun Kyung Cho; Joo-Hang Kim; Doina Ganea; Tudor Ciuleanu; Ekaterina Popova; Dina Sakaeva; Marian Stresko; Pavol Demo; Robert Godal; Yu-Feng Wei; Yen-Hsun Chen; Te-Chun Hsia; Kang-Yun Lee; Huang-Chih Chang; Chin-Chou Wang; Afshin Dowlati; Christopher Sumey; Steven Powell; Jonathan Goldman; Juan Jose Zarba; Emilio Batagelj; Andrea Viviana Pastor; Mauro Zukin; Clarissa Serodio da Rocha Baldotto; Luis Alberto Schlittler; Aknar Calabrich; Claudia Sette; Asen Dudov; Caicun Zhou; Hervé Lena; Susanne Lang; Zsuzsanna Pápai; Koichi Goto; Shigeki Umemura; Kenya Kanazawa; Yu Hara; Masahiro Shinoda; Masahiro Morise; Jeroen Hiltermann; Robert Mróz; Andrei Ungureanu; Igor Andrasina; Gee-Chen Chang; Ihor Vynnychenko; Yaroslav Shparyk; Anna Kryzhanivska; Helen Ross; Kailhong Mi; Rodney Jamil; Michael Williamson; Joseph Spahr; Zhigang Han; Mengzhao Wang; Zhixiong Yang; Jie Hu; Wei Li; Jun Zhao; Jifeng Feng; Shenglin Ma; Xiangdong Zhou; Zongan Liang; Yi Hu; Yuan Chen; Minghong Bi; Yongqian Shu; Kejun Nan; Jianying Zhou; Wei Zhang; Rui Ma; Nong Yang; Zhong Lin; Gang Wu; Jian Fang; Helong Zhang; Kai Wang; Zhendong Chen

doi:10.1016/s1470-2045(20)30539-8

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30539-8 ◽

2021 ◽

Vol 22 (1) ◽

pp. 51-65 ◽

Cited By ~ 1

Author(s):

Jonathan W Goldman ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(19)32222-6 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1929-1939 ◽

Cited By ~ 172

Author(s):

Luis Paz-Ares ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00228-2 ◽

2021 ◽

Vol 397 (10274) ◽

pp. 592-604 ◽

Cited By ~ 3

Author(s):

Ahmet Sezer ◽

Saadettin Kilickap ◽

Mahmut Gümüş ◽

Igor Bondarenko ◽

Mustafa Özgüroğlu ◽

...

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30608-3 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1454-1466 ◽

Cited By ~ 300

Author(s):

Yi-Long Wu ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30167-6 ◽

2019 ◽

Vol 20 (7) ◽

pp. 924-937 ◽

Cited By ~ 202

Author(s):

Howard West ◽

Michael McCleod ◽

Maen Hussein ◽

Alessandro Morabito ◽

Achim Rittmeyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Abstract C122: A randomized, multicenter, open-label, phase 2 study of paclitaxel-carboplatin (PC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus PC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

10.1158/1535-7163.targ-15-c122 ◽

2015 ◽

Author(s):

David Spigel ◽

Alexander Luft ◽

Rodryg Ramlau ◽

Mazen Khalil ◽

Joo-Hang Kim ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

Annals of Oncology ◽

10.1093/annonc/mdv586.02 ◽

2015 ◽

Vol 26 ◽

pp. ix161 ◽

Cited By ~ 10

Author(s):

K. Park ◽

E.-H. Tan ◽

L. Zhang ◽

V. Hirsh ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups

Annals of Oncology ◽

10.1093/annonc/mdu349.11 ◽

2014 ◽

Vol 25 ◽

pp. iv430 ◽

Cited By ~ 1

Author(s):

M.A. Socinski ◽

L. Paz-Ares ◽

A.V. Luft ◽

A. Szczesna ◽

T.E. Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text